Literature DB >> 14749919

Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.

Guido Filler1.   

Abstract

In order to allow a similar algorithm to be used for both adults and children on tacrolimus-based and mycophenolate mofetil [MMF, a pro-drug for mycophenolic acid (MPA)]-based immunosuppression, a limited sampling technique from the trough level (C0) and the levels 30 min (C0.5) and 2 h (C2) after intake was to be developed from MPA area under the time-concentration curves (AUC). We retrospectively analyzed 49 full ten-point pharmacokinetic (PK) profiles from 29 pediatric patients on MMF and tacrolimus. We used stepwise multiple regression analysis to calculate limited sampling approaches. Agreement with the AUC was tested by means of Bland and Altman analysis. The correlation between AUC and pre-dose trough concentration was r(2)=0.5188 ( P<0.0001) and between AUC and post-dose trough concentration r(2)=0.6924 ( P<0.0001). The next best correlations were with 2 h (C2, r(2)=0.6711, P<0.0001), 4 h (C4, r(2)=0.6411, P<0.0001), 1.5 h (C1.5, r(2)=0.6344, P<0.0001), and 6 h (C6, r(2)=0.6219, P<0.0001). Three-point estimates at C0, C0.5, and C2 resulted in an acceptable correlation between predicted AUC and AUC from the full profile when we used the formula AUC = 10.01391+3.94791xC0+3.24253xC0.5+1.0108xC2, Pearson's r=0.8996, 95% confidence interval 0.8277-0.9424. However, even better results could be obtained when we used AUC = 8.217+3.163xC0+0.994xC1+1.334xC2+4.183xC4, Pearson's r=0.9456, 95% confidence interval 0.9051-0.9691. Bland and Altman analysis revealed good agreement between AUC predicted from C0, C0.5, and C2 and AUC from the full profile, but was inferior to the four-point approach. Also, the previously reported formula derived for adults was not usable in these patients. A special formula must be used for children. The AUC of MPA can be predicted by limited sampling including C0, C0.5, and C2, while an approach using C0, C1, C2, and C4 is preferable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749919     DOI: 10.1007/s00147-003-0678-z

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  11 in total

1.  Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study.

Authors:  Joanna Sobiak; Matylda Resztak; Tomasz Pawiński; Paweł Żero; Danuta Ostalska-Nowicka; Jacek Zachwieja; Maria Chrzanowska
Journal:  Eur J Clin Pharmacol       Date:  2019-06-06       Impact factor: 2.953

Review 2.  The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.

Authors:  Guido Filler; Ana Catalina Alvarez-Elías; Christopher McIntyre; Mara Medeiros
Journal:  Pediatr Nephrol       Date:  2016-02-26       Impact factor: 3.714

3.  Developmental changes of MPA exposure in children.

Authors:  Elisa C Yoo; Ana Catalina Alvarez-Elías; Ekaterina Kirilova Todorova; Guido Filler
Journal:  Pediatr Nephrol       Date:  2016-01-07       Impact factor: 3.714

4.  Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients.

Authors:  Sabine Irtan; Said Azougagh; Caroline Monchaud; Michel Popon; Véronique Baudouin; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

5.  Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.

Authors:  Noël Zahr; Zahir Amoura; Jean Debord; Jean-Sébastien Hulot; Franck Saint-Marcoux; Pierre Marquet; Jean Charles Piette; Philippe Lechat
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients.

Authors:  Pei-Jun Zhou; Da Xu; Zi-Cheng Yu; Xiang-Hui Wang; Kun Shao; Ju-Ping Zhao
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients.

Authors:  Paola Krall; Dominique Yañez; Angélica Rojo; Ángela Delucchi; Miguel Córdova; Jorge Morales; Pía Boza; Alonso de la Rivera; Natalie Espinoza; Natalia Armijo; Luis E Castañeda; Mauricio J Farfán; Carolina Salas
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

8.  A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Authors:  Joanna Sobiak; Matylda Resztak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-04       Impact factor: 2.441

9.  Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease.

Authors:  Guido Filler; Ajay Parkash Sharma; Deborah M Levy; Abeer Yasin
Journal:  Pediatr Rheumatol Online J       Date:  2010-01-04       Impact factor: 3.054

10.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.